Home | Publications | Diseases | Diabetes place holder
place holder place holder

Diabetes

World Diabetes Market, The

2005-2011

Publication Date   March 2006
Publisher   Visiongain
Product Type   Report
Pages   176
ISBN Number   not applicable
Product Code   VIS029
Ask a question about this product?

Price £1,499.00

approximately: $2,647 | €1,901

Summary


Please Note: Reports are sold based on the user licenses indicated.The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.

The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs - $8.19 billion - and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.

Key Market for the Future...

Visiongain predicts that the retail market for diabetes medications will continue to show significant growth for what is an already large market. Actos from Takeda is the leading oral anti-diabetic product and appears set to retain this status. However, it is co-marketed with Eli Lilly which has new products to make available. Lantus from Sanofi-Aventis is the leading insulin product. But there are three new products available, including the world's first inhaled insulin product - Exubera from Pfizer.

Why you should buy this report:

  • Diabetes treatment is a leading therapeutic area and is about to become even more important.
  • The world's first inhaled insulin product has just been approved to the world's largest pharmaceutical company. This report will help you to assess just what impact that this is likely to have.
  • The market is dominated by a Japanese product - is this a sign of things to come from a previously struggling side of the industry?
  • Visiongain has taken the latest available financial statistics and forecast revenue figures for all the leading products.
  • The report contains analysis of the pipeline and potential blockbuster products of the next five years.

Content


  • 1. Executive Summary
    • 1.1 The Global Diabetes Market Will Exceed $21 Billion by 2011
    • 1.2 Aims, Scope and Format of the Report
    • 1.3 Research Methodology
  • 2. Introduction: A Background to Diabetes
    • 2.1 Diabetes and Insulin
    • 2.2 The Biology of Diabetes Mellitus
    • 2.3 Metabolic Syndrome and Its Relationship to Diabetes
    • 2.4 Type 1 Diabetes Described
    • 2.5 Causes of Type 1 Diabetes
      • 2.5.1 Auto-immune Response
      • 2.5.2 Genetic Abnormalities
      • 2.5.3 Viruses
      • 2.5.4 Cow's Milk
    • 2.6 Symptoms of Type 1 Diabetes
      • 2.6.1 Hypoglycemia
      • 2.6.2 Ketoacidosis
    • 2.7 Type 2 Diabetes Described
    • 2.8 Causes of Type 2 Diabetes
      • 2.8.1 Insulin Resistance
      • 2.8.2 Genetic Factors
    • 2.9 Symptoms of Type 2 Diabetes
    • 2.10 Gestational Diabetes
    • 2.11 Maturity-onset Diabetes in Youth
    • 2.12 Secondary Diabetes
    • 2.13 Diagnosing Diabetes
    • 2.14 New Diagnostic Guidelines
    • 2.15 Pre-diabetes
    • 2.16 Further Health Consequences of Diabetes
    • 2.16.1 Cardiovascular Disease
    • 2.16.2 Kidney Disease
    • 2.16.3 Blindness
    • 2.16.4 Nervous System Disease and Amputations
    • 2.16.5 Dental Disease
    • 2.16.6 Impotence
    • 2.16.7 Complications in Pregnancy
    • 2.17 Diabetes Tests
    • 2.17.1 Fasting Plasma Glucose (FPG) Test
    • 2.17.2 Glucose Tolerance Test
    • 2.17.3 Test for Glycosylated Haemoglobin
    • 2.17.4 Fructosamine
    • 2.18 Specific Goals of DiabetesTreatment
    • 2.18.1 Benefits of Improved Blood Sugar Control
    • 2.19 Diabetes Risk Factors
    • 2.19.1 Type 1 Diabetes Risk Factors
    • 2.19.2 Type 2 Diabetes Risk Factors
    • 2.19.3 Age of 40 Years or Older
    • 2.19.4 Obesity and Physical Inactivity
    • 2.19.5 Family History of Diabetes
    • 2.19.6 Diabetes During Pregnancy
    • 2.19.7 Ethnicity
    • 2.19.8 Low Birth Weight
    • 2.20 Diabetes Prevalence Will Increase to 370m by 2030
  • 3. The Treatment of Type 1 Diabetes
    • 3.1 Introduction to Insulin
    • 3.2 Types of Available Insulin
      • 3.2.1 Rapid-acting Insulin
      • 3.2.2 Start-activity Insulin
      • 3.2.3 Intermediate-acting Insulin
      • 3.2.4 Long-acting Insulin
      • 3.2.5 Ultra-long-acting Insulin
      • 3.2.6 Insulin Mixtures
    • 3.3 Insulin: A Background to Manufacture
    • 3.4 Insulin Analogues and Proinsulin
    • 3.5 Insulin as a Biogeneric
    • 3.6 Exubera: A Revolution in Diabetes Healthcare
    • 3.7 Extensive Meets Unmet Medical Need
    • 3.8 Exubera - Successful Clinical Trials
    • 3.9 Continued Safety Concerns
    • 3.10 Exubera a Future Blockbuster But When?
  • 4. The Treatment of Type 2 Diabetes
    • 4.1 Various Drug Treatments Are Available
    • 4.2 Classes of Medication
      • 4.2.1 Sulphonyureas
      • 4.2.2 Prandial Glucose Regulators (PGR)
      • 4.2.3 Meglitinides
      • 4.2.4 Biguanides
      • 4.2.5 Thiazolidinediones
      • 4.2.6 Alpha-glucosidase Inhibitors
    • 4.3 The Treatment of type 2 Diabetes by Lifestyle Measures
      • 4.3.1 Diet and Weight Loss
      • 4.3.2 Exercise
      • 4.3.3 Monitoring Blood Glucose
      • 4.3.4 Daily Foot Care
  • 5. The World Diabetes Market, 2005-2011
    • 5.1 Growth Rates in the World Diabetes Market Will Increase in 2007 due to Exubera
    • 5.2 Oral Anti-diabetics Dominate the World Diabetes Market
    • 5.3 Thiazolidinediones Are the Leading Oral Anti-diabetic Drugs
    • 5.4 Takeda Leads the World's Diabetes Market With Actos
    • 5.5 The Price of Insulins and Oral Anti-diabetic Drugs
      • 5.5.1 Exbuera Will Be More Expensive Than Other Insulins
  • 6. The World Thiazolidinediones Market, 2005-2011
    • 6.1 GSK and Takeda Compete for Dominance in the Thiazolidinedione Market
  • 7. The World Sulphyonlyureas Market, 2005-2011
    • 7.1 Sulphyonlyureas Are the Second Most Popular Drug Class in the World Oral Anti-diabetics Market
    • 7.2 Amaryl Dominates the Sulphyonlyurea Class But Will See Declining Revenues Due to Patent Loss
  • 8. The World Biguanides Market, 2005-2011
    • 8.1 Glucophage Will Continue to Earn High Revenues Despite Patent Loss
    • 8.2 Glucophage: A lesson in Life-Cycle Management
  • 9. The World PGR Market, 2005-2011
    • 9.1 Starlix and NovoNorm: A History
  • 10. The World AGI Market, 2005-2011
    • 10.1 The AGI Market Will Show Negative Growth at the End of the Forecast Period
  • 11. The World IM and PPARs Market: New Classes of Oral Anti-diabetics
    • 11.1 Incretin Mimetic
    • 11.2 PPAR
    • 11.3 Byetta Will Earn Blockbuster Revenues by 2011
    • 11.4 Pargluva Will Initially Earn Only Small Revenues After Its Potential Launch in 2010
  • 12. The World Diabetes Market by Country, 2005
    • 12.1 The US Takes Over 55% of the World Diabetes Market
    • 12.2 Oral Anti-diabetic Drugs Generate Higher Revenues than the Insulins
    • 12.3 In the US Nearly 70% of All Diabetic Revenues Come from Anti-diabetic Drugs
    • 12.4 Generics in the US Take Nearly 20% of the Market for Oral Anti-diabetics
    • 12.5 In 2004 Lantus Was the Biggest Selling Individual Insulin Product in the US Market
    • 12.6 The Japanese Oral Anti-diabetic Market Shows Low Growth
    • 12.7 The Japanese Insulin Market Is Dominated by Novo Nordisk
  • 13. The World Insulins Market, 2005-2011
    • 13.1 The World Insulin Market Will Be Worth Over $11bn By 2011
  • 14. Pipeline for Diabetic Treatments
    • 14.1 Unmet Needs for Diabetes Treatments
    • 14.2 Leading Pipeline Products for the Diabetes Market
    • 14.3 Other Agents in Development for Treating Diabetes
      • 14.3.1 Agents in Phase III of Clinical Development
      • 14.3.2 Agents That Have Completed Phase III of Clinical Development
      • 14.3.3 Other Agents For Which Final Regulatory Approval Is Pending
    • 14.4 Other Experimental Studies: Can Immunosuppressant Drugs and Insulin Treatments Suppress Development of Type 1 Diabetes?
  • 15. Insulin Delivery Technologies
    • 15.4 Insulin Jet Injectors
    • 15.5 External Insulin Pumps
  • 16. Promising New Technology for the Treatment of Type 1 Diabetes
    • 16.1 Implantable Insulin Pumps 16.2 Insulin Pills
    • 16.3 Transdermal Insulin
    • 16.4 Oral Spray Insulin 16.5 Organ Transplantation
  • 17. An Analysis of Factors That Influence the Diabetes Market: A SWOT Analysis
    • 17.1 SWOT Analysis of the Diabetes Market
    • 17.2 An Expanding Patient Population Is the Principal Driver in the Diabetes Market
    • 17.3 The Diabetes Market Has Opportunities for Continuing Growth
    • 17.4 Advances in Technology Are Likely to Bring Benefits to the Market
    • 17.5 Generics Pose the Most Significant Threat to the World Diabetes Market
    • 17.6 Generics are the Largest Threat to the Branded Diabetes Market
    • 17.7 What Unmet Market Needs Exist in the Diabetes Market? - Experts Provide Their Views
    • 17.8 Important Patient Sub-populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
    • 17.9 Improvements in Transplantation Success and Stem Cell Research will Reduce the Market for Insulin
  • 18. Conclusion - Diabetes Is a Growing Market in Both Developed and Developing Countries
  • List of Tables
    • Table 2.1 Main Insulin Products Mentioned in the Report by Company, 2006
    • Table 2.2 Main Oral Anti-diabetic Products Mentioned in the Report by Company With US Patent Expiry Dates, 2006
    • Table 2.3 Diagnosis by the Fasting Plasma Glucose Test
    • Table 2.4 Top Ten Countries for Highest Estimated Cases of Diabetes, 2000 and 2030
    • Table 2.5 Leading Causes of Death in the US, 2002
    • Table 3.1 Types of Insulin
    • Table 4.1 Oral Anti-diabetic Drugs Currently Available
    • Table 5.1 Forecast Revenue ($m) and Growth Rate (%) for Insulin and Oral Anti-diabetics, 2004-2011
    • Table 5.2 Market Share of Insulin and Oral Anti-diabetics, 2005
    • Table 5.3 Market Share of Insulin and Oral Anti-diabetics, 2011
    • Table 5.4 Forecast Revenue ($m) and Growth Rate (%) for the Classes of Oral Anti-diabetics, 2004-2011
    • Table 5.5 Market Share of Insulin and Oral Anti-diabetics, 2005
    • Table 5.6 Market Share of Insulin and Oral Anti-diabetics, 2011
    • Table 5.7 Company Market Share (%), Insulin and Oral Anti-diabetic Drugs, 2005
    • Table 5.8 Company Market Share (%), Insulin and Oral Anti-diabetic Drugs, 2011
    • Table 5.9 Drug Prices ($) For Insulin and Oral Anti-diabetics, 2006
    • Table 6.1 Forecast Revenue ($m) and Growth Rate (%) for Insulin and Oral Anti-diabetics, 2004-2011
    • Table 6.2 Company Market Share (%) for the Thiazolidinedione Class, 2005 and 2011
    • Table 7.1Forecast Revenue ($m) and Growth Rate (%) for the Sulphonylureas, 2004-2011
    • Table 8.1 Forecast Revenue ($m) and Growth Rate (%) for the Biguanides, 2004-2011
    • Table 9.1 Forecast Revenue ($m) and Growth Rate (%) for the PGRs, 2004-2011
    • Table 10.1 Forecast Revenue ($m) and Growth Rate (%) for the AGIs, 2004-2011
    • Table 11.1 Forecast Revenue ($m) and Growth Rate (%) for the Incretin Mimetic Class, 2004-2011
    • Table 12.1 Total Diabetes Revenues (Oral and Insulins Combined) ($m) by Country, 2004
    • Table 12.2 Total Insulin Revenues ($m) by Country, 2004
    • Table 12.3 Total (Branded Only) Oral Anti-diabetic Drug Revenue ($m) by Country, 2004
    • Table 12.4 Market Share (%) for Insulins and Oral Anti-diabetic Drugs by Country, 2004
    • Table 12.5 Ratio of Insulin/Oral Use by Revenue (as %) Per Country, 2004
    • Table 12.6 US Revenues ($m) for Branded and Generic Oral Anti-diabetics, 2004
    • Table 12.7 Insulin Revenues ($m) From The US Market, 2004
    • Table 12.8 Company Revenue ($m) and Market Share (%) for Insulins on the US Market, 2004
    • Table 12.9 Japan Oral Anti-diabetic Market, 2004
    • Table 12.10 Japanese Oral Anti-diabetic Market Share (%) by Company, 2004
    • Table 12.11 Japanese Insulin Market ($m), 2005
    • Table 12.12 Japanese Insulin Market Share (%) by Company, 2004
    • Table 12.13 Revenues ($m) For The European Oral Anti- diabetic Market, 2004
    • Table 12.14 Market Share (%) for Branded and Generic Oral Anti-diabetic Drugs by European Country, 2004
    • Table 12.15 Revenues ($m) For The European Oral Anti- diabetic Market, 2004
    • Table 12.16 Revenues ($m) For The European Insulin Market, 2004
    • Table 12.17 Company Market Share (%) For Insulin Products for the European Market, 2004
    • Table 12.18 Diabetes Market Revenues ($m) for India and China, 2004
    • Table 12.19 Market Share (%) For Oral Anti-diabetics and Insulin For India and China, 2004
    • Table 13.1 Forecast Revenue ($m) and Growth Rate (%) of the World Insulin Market, 2004-2011
    • Table 13.2 Company Market Share (%) of the World Insulin Market, 2005
    • Table 13.3 Major Insulin Products by Company, 2006
    • Table 13.4 Company Market Share (%) of the World Insulin Market, 2011
    • Table 14.1 Leading Pipeline Products, 2005/6
    • Table 14.2 Agents for Diabetes in Phase III of Clinical Development
    • Table 14.3 Agents for Diabetes that Have Completed Phase III of Clinical Development
    • Table 14.4 Agents for Diabetes for Which Final Regulatory Approval Is Pending
    • Table 14.5 Other Agents in Clinical Development, by Country
    • Table 15.1 Syringes for Administering Insulin
    • Table 15.2 Insulin Pens Available in the US, 2006
    • Table 15.3 US Aids for Injection, 2006
    • Table 15.4 Types of US Insulin Jet Injectors, 2006
    • Table 15.5 US External Insulin Pumps, 2006
    • Table 17.1 Patent Expiration of the Leading Diabetes Treatments, 2006
  • List of Figures
    • Figure 5.1 Forecast Revenue ($m) for Insulin and Oral Anti-diabetics, 2004-2011
    • Figure 5.2 Growth Rates of World Diabetes Market ($bn), 2004-2011
    • Figure 5.3 Revenues ($bn) for Insulin and Oral Anti-diabetics, 2004-2011
    • Figure 5.4 Revenues ($bn) for Insulin and Oral Anti-diabetics, 2004-2011
    • Figure 5.5 Growth Rates (%) for Insulin and Oral Anti- diabetics, 2004-2011
    • Figure 5.6 Market Share (%) for Insulin and Oral Anti-diabetics, 2005
    • Figure 5.7 Market Share (%) for Insulin and Oral Anti-diabetics, 2011
    • Figure 5.8a Forecast Revenue ($m) for the Classes of All Oral Anti-diabetics, 2004-2011
    • Figure 5.8b Forecast Revenue ($m) for the Classes of Oral Anti-diabetics But Not Including the Thiazolidiones, 2004-2011
    • Figure 5.9 Market Share (%) for Oral Anti-diabetics, 2005
    • Figure 5.10 Market Share (%) for Oral Anti-diabetics, 2011
    • Figure 5.11 Company Market Share Insulin and Oral Anti- diabetic Drugs, 2005
    • Figure 5.12 Company Market Share Insulin and Oral Anti-diabetic Drugs, 2011
    • Figure 6.1 Forecast Revenue ($m) for the Thiazolidinedione Class of Oral Anti-diabetics, 2004-2011
    • Figure 6.2 Market Share (%) of the Thiazolidinediones, 2005
    • Figure 6.3 Market Share (%) of the Thiazolidinediones, 2011
    • Figure 7.1 Forecast Revenue ($m) for the Sulphonylurea Class of Oral Anti-diabetics, 2004-2011
    • Figure 7.2 Market Share (%) of the Sulphonylureas, 2005
    • Figure 7.3 Market Share (%) of the Sulphonylureas, 2011
    • Figure 8.1 Forecast Revenue ($m) the Biguanide Class of Oral Anti-diabetics, 2004-2011
    • Figure 9.1 Forecast Revenue ($m) the PGRs Class of Oral Anti-diabetics, 2004-2011
    • Figure 9.2 Market Share (%) of the PGRs, 2005
    • Figure 9.3 Market Share (%) of the PGRs, 2011
    • Figure 10.1 Forecast Revenue ($m) for the AGIs Class of Oral Anti-diabetics, 2004-2011
    • Figure 10.2 Market Share (%) of the AGIs, 2005
    • Figure 10.3 Market Share (%) of the AGIs, 2011
    • Figure 11.1 Forecast Revenue ($m) the Incretin Mimetic Class of Oral Anti-diabetics, 2004-2011
    • Figure 12.1 Total Diabetes Revenues (Oral and Insulins Combined) ($m) by Country, 2004
    • Figure 12.2 Total Insulin Market Share (%) by Country, 2004
    • Figure 12.3 Total (Branded Only) Oral Anti-diabetic Market Share (%) by Country, 2004
    • Figure 12.4 Market Share (%) for Insulins and Oral Anti-diabetic Drugs by Country, 2004
    • Figure 12.5 Ratio of Insulin/Oral Anti-diabetic by Revenue (as %) by Country
    • Figure 12.6 Market Share (%) for Branded and Generic Oral Anti-diabetics, 2004
    • Figure 12.7 Company Market Share (%) for Insulins on the US Market, 2004
    • Figure 12.8 Company Market Share (%) for Insulins on the Japanese Market, 2004
    • Figure 12.9 Market Share (%) For Branded and Generic Diabetes Drugs In The Leading EU Markets, 2004
    • Figure 12.10 Revenue ($m) of Leading Insulin Products in European Market, 2004
    • Figure 12.11 Company Market Share (%) For Insulin Products For the European Market, 2004
    • Figure 13.1 Forecast Revenues ($m) for the World Insulin Market, 2005-2011
    • Figure 13.2 Company Market Share (%) of the World Insulin Market, 2005
    • Figure 13.3 Company Market Share (%) of the World Insulin Market, 2011
    • Figure 13.3 Forecast Revenues ($m), For the Leading Insulin Products, 2004-2011
    • Figure 13.5 Company Market Share (%) of the Insulin Market, 2011
    • Figure 14.1 Patient Preference for Exubera Insulin
    • Figure 15.1 Locations for Injecting Insulin
    • Figure 17.1 SWOT Chart for the Diabetes Market, 2005-2011
    • Figure 18.1 The World Diabetes Market by Revenue ($m), 2004-2011